

**NAVANA PHARMA****NAVANA PHARMACEUTICALS PLC.**Corporate Office : House # 99, Road # 04, Block # B,  
Banani, Dhaka -1213**PRICE SENSITIVE INFORMATION**

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 48<sup>th</sup> meeting held on 14<sup>th</sup> November, 2024 ended at 5.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the first quarter (Q1) period ended on September 30, 2024 and took the following Price Sensitive Decision:-

**Comparative Statement on Un-audited Financial Statement for the first quarter (Q1) of financial year-2024-2025 period ended on September 30, 2024:**

Sl. No	Particulars	01.07.2024-30.09.2024	01.07.2023-30.09.2023
I	Earnings Per Share (EPS)	1.25	1.11
ii	Net Operating Cash Flow Per Share (NOCFPS)	2.00	1.19
		<b>As at 30.09.2024</b>	<b>As at 30.06.2024</b>
iii	Net Asset Value (NAV)	4,674,043,449	4,561,095,559
iv	Net Asset Value Per Share	43.51	42.46

**Notes:****★ Reasons of significant deviation in earning per share (EPS) & Net Operating Cash Flow per Share (NOCFPS) between the quarterly periods:**

- EPS: Increase in Sales Revenue and efficient usages of material resulted in increased gross profit for the reporting period resulted in the increment of Earnings per Share (EPS) by 12.6% as well.
- NOCFPS: Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 2.00 from Tk. 1.19, due to cash received from the customers was higher than the cash payment to the vendors in the reporting period.

- ★ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-audited Financial Statement for the first quarter (Q1) period ended on September 30, 2024 in two widely circulated daily newspapers (one in Bengali and otherone in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website ([www.navanapharma.com](http://www.navanapharma.com)) of the company.

Dated: November 14, 2024

By order of the Board  
Sd/-**Lorens Shamol Mollick FCS**  
Company Secretary